文献速递肿瘤 PET/CT

基线18F-FDG PET/CT在HPV阳性与阴性口咽癌患者中的预后价值

The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirus-Positive Versus Human Papillomavirus-Negative Patients With Oropharyngeal Cancer.
PubMed 文献 · Clin Nucl Med · 2019-01-01

本研究回顾性分析201例接受放化疗的口咽癌患者,评估基线FDG PET/CT代谢参数(SUVmax、SUVpeak、MTV、TLG)的预后价值,并比较HPV阳性与阴性患者的差异。结果显示HPV阴性肿瘤的上述参数均显著更高;在多变量分析中,仅HPV阴性患者的总病灶糖酵解(TLG)与无病生存期(DFS)显著相关,HPV阳性患者中未观察到该关联。

要点

  • HPV阴性口咽癌的SUVmax、SUVpeak、MTV和TLG均显著高于HPV阳性。
  • 多变量分析中,仅HPV阴性患者TLG与DFS显著相关(HR 1.005)。
  • HPV阳性患者中未观察到TLG与DFS的关联。

核心结论

  • 基线TLG升高与HPV阴性口咽癌患者更差的无病生存期相关,可能作为该人群风险分层的生物标志物;HPV阳性患者中未发现该关联。

研究设计与样本

  • 回顾性研究,纳入201例接受放化疗的口咽癌患者,其中109例为HPV阳性。

主要发现

  • MTV与TLG强相关(r=0.96),SUVpeak与SUVmax强相关(r=0.97)。
  • PET参数与HPV状态和T分期相关性最强,二者解释MTV变异的40%和TLG变异的33%。
  • HPV阴性肿瘤的SUVmax、SUVpeak、MTV和TLG均显著更高。
  • 单变量分析中所有PET参数均与局部控制、总生存和无病生存显著相关。
  • 多变量分析中,HPV阴性患者TLG与DFS显著相关(HR 1.005,95%CI 1.001-1.010,P=0.03),HPV阳性患者中未观察到。

临床怎么用

  • 对HPV阴性口咽癌患者,可考虑将基线TLG用于风险分层,辅助识别高复发风险者。

局限性

  • 回顾性研究设计;摘要未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oropharynx cancer (OPC) is heterogeneous; human papillomavirus (HPV)-positive and HPV tumors represent 2 disease entities with a different prognosis. Earlier studies investigating the prognostic value of pretreatment F-FDG PET in OPC are small or included patients with unknown HPV status. This study assessed the prognostic value of PET variables, in a large cohort with balanced HPV status. METHODS: Retrospectively, primary tumor SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were extracted from baseline FDG PET/CT of patients with OPC treated with (chemo)radiation. The Pearson correlation between the PET variables was calculated. With linear regression, the correlation between the PET variables and HPV status, age, smoking status, T stage, N stage, and American Joint Committee on Cancer stage was calculated. Univariable and multivariable Cox models analyzed local control, overall survival, and disease-free survival (DFS). RESULTS: Of 201 patients, 109 were HPV. Metabolic tumor volume and TLG correlated (r = 0.96), as did SUVpeak and SUVmax (r = 0.97). The PET variables correlated strongest with HPV status and T stage. These two accounted for 40% of the variance of MTV and 33% of TLG. Human papillomavirus-negative tumors had a significantly higher SUVmax, SUVpeak, MTV, and TLG. In univariable analysis, all PET variables were significantly associated with local control, overall survival, and DFS. In multivariable analysis, TLG was significantly associated to DFS in patients with HPV OPC (hazard ratio, 1.005; 95% confidence interval, 1.001-1.010; P = 0.03). However, we did not observe this in HPV patients. CONCLUSIONS: Increased baseline TLG is associated with worse DFS in HPV OPC and might be used as biomarker for risk stratification in these patients. Interestingly, we could not identify this association in HPV patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gouw ZAR, La Fontaine MD, van Kranen S, et al. The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirus-Positive Versus Human Papillomavirus-Negative Patients With Oropharyngeal Cancer. Clin Nucl Med. 2019. PMID: 30889002. doi:10.1097/RLU.0000000000002531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。